Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma

摘要: Although numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma (HCC) has not clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed this study with new effective drug combination. Twenty-nine patients histologically-confirmed, metastatic HCC received a combination doxorubicin 60 mg/m2 cisplatin on day 1, plus capecitabine 2000 mg/m2/day as an intermittent regimen 2 weeks treatment followed by 1-week rest. The median age was 49 years (range, 32–64) 19 were hepatitis B virus seropositive. Child-Pugh class A in all 4 had Zubrod performance status 2. objective response rate 24% (95% CI 9–40) 6 stable diseases. generally well tolerated despite one treatment-related death. Combination doxorubicin, produced modest antitumor activity tolerable adverse effects HCC.